Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Recurrence 1Lymphoma, T-Cell, Peripheral 1Lymphoma 1

Interventions

Cyclophosphamide 47Rituximab 34Exercise 25fludarabine phosphate 24Methotrexate 24Blood Specimen Collection 23Vincristine 21Cytarabine 21Radiotherapy 20Filgrastim 19Peripheral Blood Stem Cell Transplantation 18Whole-Body Irradiation 17Prednisone 16Melphalan 16Etoposide 16Cyclosporine 16Methods 15Dexamethasone 15Busulfan 15Antilymphocyte Serum 15fludarabine 14Doxorubicin 14Educational Status 13Mycophenolic Acid 12Magnetic Resonance Spectroscopy 11Early Intervention, Educational 11Therapeutics 10Surveys and Questionnaires 9Standard of Care 9Prednisolone 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Immunoconjugates × Lymphoid × Clear all
NCT01841021 2017-01-19

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Terminated
1 enrolled 5 charts
Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

NCT01671813 2013-07-25

Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Withdrawn
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡